Business · 02/01/2018Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of 111 Abbreviated New Drug Applications from Multiple Applicants
Summary
The US Food and Drug Administration (FDA) has withdrawn the approval of 111 abbreviated new drug applications (ANDAs) from various applicants, following written notifications from the applicants that the corresponding drug products are no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →